跳至主要内容
临床试验/CTRI/2018/08/015146
CTRI/2018/08/015146尚未招募4 期

Clinical Evaluation of Drakshavaleha in the Management of Pandu (Iron Deficiency Anaemia). - DIIDA

Central Council For Research In Ayurvedic Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Patients of either sex aged between18 to 50 years.
  • 2. IDA documented by hematologic indices.
  • i. Hb 8gm-10gm. %
  • ii. S.Ferritin < 12 ng /mL
  • iii. TIBC >450mcg/dL
  • iv. S.Iron <60μg/dL for male; <50 μg/dL for female
  • v. MCV <80fL/redcell
  • vi. RDW >46fL
  • vii. Reticulocyte count <0.5%
  • (Among these the first 3 are the essential criteria for inclusion)
  • 3. Willing and able to participate for 112 days.

排除标准

  • 1. Iron deficiency likely or definitely due to blood loss from the intestine or other sites.
  • 2. History or evidence of intestinal malabsorption
  • 3. Patients suffering from major systemic illness necessitating long term drug
  • treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, Bleeding
  • disorders, etc.)
  • 4. Other causes of Anemia (sickle cell disease, thalassemia, other hemolyticAnemia,
  • bone marrow failure, etc.) apparent by history, physical examination, and/or
  • laboratory tests.
  • 5. Patients on prolonged ( > 6 weeks) medication with corticosteroids,
  • antidepressants,anticholinergics, etc. or any other drugs that may have an influence
  • on the outcome of the study.
  • 6. Patients with concurrent serious hepatic disorder (defined as Aspartate
  • AminoTransferase (AST) and / or Alanine Amino Transferase (ALT), Total
  • Bilirubin, AlkalinePhosphatase (ALP) > 2 times upper normal limit), or Renal
  • Disorders (defined as S. Creatinine >1.2mg/dL), Total Serum Cholesterol & / or
  • Serum Triglycerides > 250 mg/dl, Severe PulmonaryDysfunction (uncontrolled
  • Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease[COPD]).
  • 7. Alcoholics and/or drug abusers

研究者

相似试验